Gennaro Musi

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/7580184/publications.pdf

Version: 2024-02-01

201674 276875 2,252 123 27 41 h-index citations g-index papers 126 126 126 2975 citing authors docs citations times ranked all docs

#	Article	IF	Citations
1	Robotâ€assisted simple prostatectomy (RASP): does it make sense?. BJU International, 2012, 110, E972-9.	2.5	88
2	Prostate Health Index (Phi) and Prostate Cancer Antigen 3 (PCA3) Significantly Improve Prostate Cancer Detection at Initial Biopsy in a Total PSA Range of 2–10 ng/ml. PLoS ONE, 2013, 8, e67687.	2.5	87
3	An increased body mass index is associated with a worse prognosis in patients administered BCG immunotherapy for T1 bladder cancer. World Journal of Urology, 2019, 37, 507-514.	2,2	77
4	Salvage Stereotactic Body Radiotherapy for Isolated Lymph Node Recurrent Prostate Cancer: Single Institution Series of 94 Consecutive Patients and 124 Lymph Nodes. Clinical Genitourinary Cancer, 2017, 15, e623-e632.	1.9	71
5	Systemic Inflammatory Markers and Oncologic Outcomes in Patients with High-risk Non–muscle-invasive Urothelial Bladder Cancer. European Urology Oncology, 2018, 1, 403-410.	5.4	66
6	Radiomics in prostate cancer: an up-to-date review. Therapeutic Advances in Urology, 2022, 14, 175628722211090.	2.0	62
7	Impact of Resection Technique on Perioperative Outcomes and Surgical Margins after Partial Nephrectomy for Localized Renal Masses: A Prospective Multicenter Study. Journal of Urology, 2020, 203, 496-504.	0.4	61
8	Urinary long noncoding RNAs in nonmuscle-invasive bladder cancer: new architects in cancer prognostic biomarkers. Translational Research, 2017, 184, 108-117.	5.0	56
9	Validation of Neutrophil-to-lymphocyte Ratio in a Multi-institutional Cohort of Patients With T1G3 Non–muscle-invasive Bladder Cancer. Clinical Genitourinary Cancer, 2018, 16, 445-452.	1.9	55
10	Prostate Cancer Radiogenomicsâ€"From Imaging to Molecular Characterization. International Journal of Molecular Sciences, 2021, 22, 9971.	4.1	55
11	Body mass index was associated with upstaging and upgrading in patients with low-risk prostate cancer who met the inclusion criteria for active surveillance. Urologic Oncology: Seminars and Original Investigations, 2015, 33, 201.e1-201.e8.	1.6	54
12	Thulium Laser Treatment of Upper Urinary Tract Carcinoma: A Multi-Institutional Analysis of Surgical and Oncological Outcomes. Journal of Endourology, 2018, 32, 257-263.	2.1	51
13	Reirradiation for isolated local recurrence of prostate cancer: Mono-institutional series of 64 patients treated with salvage stereotactic body radiotherapy (SBRT). British Journal of Radiology, 2019, 92, 20180494.	2.2	50
14	Absolute basophil count is associated with time to recurrence in patients with high-grade T1 bladder cancer receiving bacillus Calmette–Guérin after transurethral resection of the bladder tumor. World Journal of Urology, 2020, 38, 143-150.	2.2	49
15	Robot-assisted Radical Prostatectomy: Multiparametric MR Imaging–directed Intraoperative Frozen-Section Analysis to Reduce the Rate of Positive Surgical Margins. Radiology, 2015, 274, 434-444.	7.3	48
16	The Prognostic Role of Circulating Tumor Cells (CTC) in High-risk Non–muscle-invasive Bladder Cancer. Clinical Genitourinary Cancer, 2017, 15, e661-e666.	1.9	47
17	Neuroendocrine Differentiation in Castration-Resistant Prostate Cancer: A Systematic Diagnostic Attempt. Clinical Genitourinary Cancer, 2012, 10, 164-173.	1.9	45
18	Beyond PSA: The Role of Prostate Health Index (phi). International Journal of Molecular Sciences, 2020, 21, 1184.	4.1	45

#	Article	IF	CITATIONS
19	Modified Glasgow Prognostic Score is Associated With Risk of Recurrence in Bladder Cancer Patients After Radical Cystectomy. Medicine (United States), 2015, 94, e1861.	1.0	43
20	Neutrophil, Platelets, and Eosinophil to Lymphocyte Ratios Predict Gleason Score Upgrading in Low-Risk Prostate Cancer Patients. Urologia Internationalis, 2019, 102, 43-50.	1.3	43
21	Diagnostic Accuracy of 64 Copper Prostate-specific Membrane Antigen Positron Emission Tomography/Computed Tomography for Primary Lymph Node Staging of Intermediate- to High-risk Prostate Cancer: Our Preliminary Experience. Urology, 2017, 106, 139-145.	1.0	42
22	Type 2 diabetes mellitus predicts worse outcomes in patients with high-grade T1 bladder cancer receiving bacillus Calmette-Guérin after transurethral resection of the bladder tumor. Urologic Oncology: Seminars and Original Investigations, 2020, 38, 459-464.	1.6	42
23	Neutrophil percentage-to-albumin ratio predicts mortality in bladder cancer patients treated with neoadjuvant chemotherapy followed by radical cystectomy. Future Science OA, 2021, 7, FSO709.	1.9	40
24	Reliability of Frozen Section Examination in a Large Cohort of Testicular Masses: What Did WeÂLearn?. Clinical Genitourinary Cancer, 2017, 15, e689-e696.	1.9	39
25	Sensitivity and Detection Rate of a 12-Core Trans-Perineal Prostate Biopsy: Preliminary Report. European Urology, 2006, 49, 827-833.	1.9	35
26	Virtue male sling for postâ€prostatectomy stress incontinence: a prospective evaluation and midâ€term outcomes. BJU International, 2017, 119, 482-488.	2.5	34
27	Dose Escalation for Prostate Cancer Using the Three-Dimensional Conformal Dynamic Arc Technique: Analysis of 542 Consecutive Patients. International Journal of Radiation Oncology Biology Physics, 2008, 71, 784-794.	0.8	31
28	Acute toxicity of image-guided hypofractionated radiotherapy for prostate cancer: Nonrandomized comparison with conventional fractionation. Urologic Oncology: Seminars and Original Investigations, 2011, 29, 523-532.	1.6	28
29	Adherence to EAU guidelines on penile cancer translates into better outcomes: a multicenter international study. World Journal of Urology, 2019, 37, 1649-1657.	2.2	27
30	Predictors of Residual T1 High Grade on Re-Transurethral Resection in a Large Multi-Institutional Cohort of Patients with Primary T1 High-Grade/Grade 3 Bladder Cancer. Journal of Cancer, 2018, 9, 4250-4254.	2.5	26
31	Long-term oncologic and functional outcomes after robot-assisted partial nephrectomy in elderly patients. Minerva Urologica E Nefrologica = the Italian Journal of Urology and Nephrology, 2019, 71, 31-37.	3.9	26
32	Impact of Age on Outcomes of Patients With Pure Carcinoma In Situ of the Bladder: Multi-Institutional Cohort Analysis. Clinical Genitourinary Cancer, 2022, 20, e166-e172.	1.9	26
33	The emerging landscape of tumor marker panels for the identification of aggressive prostate cancer: the perspective through bibliometric analysis of an Italian translational working group in uro-oncology. Minerva Urology and Nephrology, 2021, 73, 442-451.	2.5	23
34	High-Grade T1 on Re-Transurethral Resection after Initial High-Grade T1 Confers Worse Oncological Outcomes: Results of a Multi-Institutional Study. Urologia Internationalis, 2018, 101, 7-15.	1.3	22
35	Multiparametric Magnetic Resonance Imaging Second Opinion May Reduce the Number of Unnecessary Prostate Biopsies: Time to Improve Radiologists' Training Program?. Clinical Genitourinary Cancer, 2019, 17, 88-96.	1.9	22
36	A novel nomogram to identify candidates for active surveillance amongst patients with International Society of Urological Pathology (ISUP) Grade Group (GG) 1 or ISUP GG2 prostate cancer, according to multiparametric magnetic resonance imaging findings. BJU International, 2020, 126, 104-113.	2.5	21

#	Article	IF	CITATIONS
37	The Impact of SARS-CoV-2 Pandemic on Time to Primary, Secondary Resection and Adjuvant Intravesical Therapy in Patients with High-Risk Non-Muscle Invasive Bladder Cancer: A Retrospective Multi-Institutional Cohort Analysis. Cancers, 2021, 13, 5276.	3.7	21
38	Multiparametric magnetic resonance imaging and frozen-section analysis efficiently predict upgrading, upstaging, and extraprostatic extension in patients undergoing nerve-sparing robotic-assisted radical prostatectomy. Medicine (United States), 2016, 95, e4519.	1.0	20
39	Low PI-RADS assessment category excludes extraprostatic extension (â%¥pT3a) of prostate cancer: a histology-validated study including 301 operated patients. European Radiology, 2019, 29, 5478-5487.	4.5	20
40	Systemic combining inflammatory score (SCIS): a new score for prediction of oncologic outcomes in patients with high-risk non-muscle-invasive urothelial bladder cancer. Translational Andrology and Urology, 2021, 10, 626-635.	1.4	20
41	Image Guided Hypofractionated Radiotherapy and Quality of Life for Localized Prostate Cancer: Prospective Longitudinal Study in 337 Patients. Journal of Urology, 2013, 189, 2099-2103.	0.4	19
42	Robot assisted radical prostatectomy in kidney transplant recipients: surgical, oncological and functional outcomes of two different robotic approaches. International Braz J Urol: Official Journal of the Brazilian Society of Urology, 2019, 45, 262-272.	1.5	19
43	Robot-assisted Partial Nephrectomy: 5-yr Oncological Outcomes at a Single European Tertiary Cancer Center. European Urology Focus, 2019, 5, 636-641.	3.1	19
44	Multiparametric Magnetic-Resonance to Confirm Eligibility to an Active Surveillance Program for Low-Risk Prostate Cancer: Intermediate Time Results of a Third Referral High Volume Centre Active Surveillance Protocol. Urologia Internationalis, 2018, 101, 56-64.	1.3	17
45	SARS-CoV-2 Infection and High-Risk Non-Muscle-Invasive Bladder Cancer: Are There Any Common Features?. Urologia Internationalis, 2020, 104, 510-522.	1.3	17
46	Thuliumâ€"yttriumâ€"aluminiumâ€"garnet (Tm:YAG) laser treatment of penile cancer: oncological results, functional outcomes, and quality of life. World Journal of Urology, 2018, 36, 265-270.	2.2	15
47	Double Loop Ureteral Stent Encrustation According to Indwelling Time: Results of a European Multicentric Study. Journal of Endourology, 2021, 35, 84-90.	2.1	14
48	Modified Glasgow Prognostic Score as a Predictor of Recurrence in Patients with High Grade Non-Muscle Invasive Bladder Cancer Undergoing Intravesical Bacillus Calmette–Guerin Immunotherapy. Diagnostics, 2022, 12, 586.	2.6	14
49	Assessment of PSIM (Prostatic Systemic Inflammatory Markers) Score in Predicting Pathologic Features at Robotic Radical Prostatectomy in Patients with Low-Risk Prostate Cancer Who Met the Inclusion Criteria for Active Surveillance. Diagnostics, 2021, 11, 355.	2.6	12
50	Impact of surgical approach and resection technique on the risk of Trifecta Failure after partial nephrectomy for highly complex renal masses. European Journal of Surgical Oncology, 2022, 48, 687-693.	1.0	12
51	The impact of surgery for lower urinary tract symptoms/benign prostatic enlargement on both erectile and ejaculatory function: a systematic review. International Journal of Impotence Research, 2019, 31, 319-327.	1.8	11
52	A Guide for Oncologic Patient Management during Covid-19 Pandemic: The Initial Experience of an Italian Oncologic Hub with Exemplificative Focus on Uro-Oncologic Patients. Cancers, 2020, 12, 1513.	3.7	11
53	Oligorecurrent Prostate Cancer and Stereotactic Body Radiotherapy: Where Are We Now? A Systematic Review and Meta-analysis of Prospective Studies. European Urology Open Science, 2021, 27, 19-28.	0.4	11
54	A novel "intuitive―surgical technique for right robot-assisted retroperitoneal lymph node dissection for stage I testicular NSGCT. World Journal of Urology, 2013, 31, 435-439.	2.2	10

#	Article	IF	CITATIONS
55	Intraoperative Frozen Pathology During Robot-Assisted Laparoscopic Radical Prostatectomy: Can ALEXISâ,,¢ Trocar Make it Easy and Fast?. Journal of Endourology, 2013, 27, 1213-1217.	2.1	10
56	Conditional survival of patients with stage lâ€"III squamous cell carcinoma of the penis: temporal changes in cancer-specific mortality. World Journal of Urology, 2020, 38, 725-732.	2.2	10
57	Association Between Systemic Therapy and/or Cytoreductive Nephrectomy and Survival in Contemporary Metastatic Non–clear Cell Renal Cell Carcinoma Patients. European Urology Focus, 2021, 7, 598-607.	3.1	10
58	Survival of contemporary patients with non-metastatic urachal vs. non-urachal adenocarcinoma of the urinary bladder. World Journal of Urology, 2020, 38, 2819-2826.	2.2	10
59	Adherence to guideline recommendations for lymph node dissection in squamous cell carcinoma of the penis: Effect on survival and complication rates. Urologic Oncology: Seminars and Original Investigations, 2019, 37, 578.e11-578.e19.	1.6	9
60	Radioablation $+/\hat{a}^{-}$ hormonotherapy for prostate cancer oligorecurrences (Radiosa trial): potential of imaging and biology (AIRC IG-22159). BMC Cancer, 2019, 19, 903.	2.6	9
61	Radical penectomy, a compromise for life: results from the PECAD study. Translational Andrology and Urology, 2020, 9, 1306-1313.	1.4	9
62	Racial and ethnic differences in survival in contemporary metastatic renal cell carcinoma patients, according to alternative treatment modalities. Cancer Causes and Control, 2020, 31, 263-272.	1.8	9
63	MRI-targeted or systematic random biopsies for prostate cancer diagnosis in biopsy naÃ-ve patients: follow-up of a PRECISION trial-like retrospective cohort. Prostate Cancer and Prostatic Diseases, 2021, 24, 406-413.	3.9	9
64	Impact of Trifecta definition on rates and predictors of "successful" robotic partial nephrectomy for localized renal masses: results from the Surface-Intermediate-Base Margin Score International Consortium. Minerva Urology and Nephrology, 2022, 74, 186-193.	2.5	9
65	Sexual function recovery after robotâ€assisted radical prostatectomy: Outcomes from an Italian referral centre and predicting nomogram. Andrologia, 2019, 51, e13385.	2.1	8
66	Pathological findings at radical prostatectomy of biopsy na \tilde{A}^- ve men diagnosed with MRI targeted biopsy alone without concomitant standard systematic sampling. Urologic Oncology: Seminars and Original Investigations, 2020, 38, 929.e11-929.e19.	1.6	8
67	Quality of life and psycho-emotional wellbeing in bladder cancer patients and their caregivers: a comparative analysis between urostomy versus ileal orthotopic neobladder. Ecancermedicalscience, 2021, 15, 1163.	1.1	8
68	External validation of the computerized analysis of TRUS of the prostate with the ANNA/C-TRUS system: a potential role of artificial intelligence for improving prostate cancer detection. World Journal of Urology, 2023, 41, 619-625.	2.2	8
69	Reporting combined outcomes with Trifecta and survival, continence, and potency (SCP) classification in 337 patients with prostate cancer treated with image-guided hypofractionated radiotherapy. BJU International, 2014, 114, E3-E10.	2.5	7
70	Meta-analysis of studies comparing oncologic outcomes of radical prostatectomy and brachytherapy for localized prostate cancer. Therapeutic Advances in Urology, 2017, 9, 241-250.	2.0	7
71	Protocol of the Italian Radical Cystectomy Registry (RIC): a non-randomized, 24-month, multicenter study comparing robotic-assisted, laparoscopic, and open surgery for radical cystectomy in bladder cancer. BMC Cancer, 2021, 21, 51.	2.6	7
72	Radiotherapy in Prostate Cancer Patients With Pelvic Lymphocele After Surgery: Clinical and Dosimetric Data of 30 Patients. Clinical Genitourinary Cancer, 2015, 13, e223-e228.	1.9	6

#	Article	IF	CITATIONS
73	Comparison of Outcomes and Toxicity Between Extreme and Moderate Radiation Therapy Hypofractionation in Localized Prostate Cancer: A Propensity Score Analysis. International Journal of Radiation Oncology Biology Physics, 2019, 105, 735-744.	0.8	6
74	Case series on multiple prostate re-irradiation for locally recurrent prostate cancer: something ventured, something gained. Neoplasma, 2019, 66, 308-314.	1.6	6
75	Impact of image guidance on toxicity and tumour outcome in moderately hypofractionated external-beam radiotherapy for prostate cancer. Medical Oncology, 2019, 36, 9.	2.5	6
76	Postoperative vacuum therapy following AMSâ,,¢ LGX 700® inflatable penile prosthesis placement: penile dimension outcomes and overall satisfaction. International Journal of Impotence Research, 2020, 32, 133-139.	1.8	6
77	Survival After Partial Cystectomy for Variant Histology Bladder Cancer Compared With Urothelial Carcinoma: A Population-based Study. Clinical Genitourinary Cancer, 2020, 18, 117-128.e5.	1.9	6
78	Contemporary Rates and Predictors of Open Conversion During Minimally Invasive Radical Prostatectomy for Nonmetastatic Prostate Cancer. Journal of Endourology, 2020, 34, 600-607.	2.1	6
79	Exploring miRNA Signature and Other Potential Biomarkers for Oligometastatic Prostate Cancer Characterization: The Biological Challenge behind Clinical Practice. A Narrative Review. Cancers, 2021, 13, 3278.	3.7	6
80	Comparison Between Micro-Ultrasound and Multiparametric MRI Regarding the Correct Identification of Prostate Cancer Lesions. Clinical Genitourinary Cancer, 2022, 20, e339-e345.	1.9	6
81	A comprehensive evaluation of sexual and reproductive outcomes following robot-assisted retroperitoneal lymph node dissection for nonseminomatous germ cell tumor. Asian Journal of Andrology, 2022, 24, 579.	1.6	6
82	Cytoreductive prostate radiotherapy in oligometastatic prostate cancer: a single centre analysis of toxicity and clinical outcome. Ecancermedicalscience, 2017, 11, 786.	1.1	5
83	Cumulative Cancer Locations is a Novel Metric for Predicting Active Surveillance Outcomes: A Multicenter Study. European Urology Oncology, 2018, 1, 268-275.	5.4	5
84	Contemporary Assessment of Survival Rates in Stage I Testicular Seminoma: A Population-Based Comparison Between Surveillance and Active Treatment After Orchiectomy. Clinical Genitourinary Cancer, 2019, 17, e793-e801.	1.9	5
85	Incidence of fatigue and low-dose corticosteroid use in prostate cancer patients receiving systemic treatment: a meta-analysis of randomized controlled trials. World Journal of Urology, 2019, 37, 1049-1059.	2.2	5
86	Survival of Contemporary Patients With Non-metastatic Small-cell Carcinoma of Urinary Bladder, According to Alternative Treatment Modalities. Clinical Genitourinary Cancer, 2020, 18, e450-e456.	1.9	5
87	Impact of Perioperative Immunonutrition on Complications in Patients Undergoing Radical Cystectomy: A Retrospective Analysis. Integrative Cancer Therapies, 2021, 20, 153473542110194.	2.0	5
88	Effect of Age on Cancer-specific Mortality in Patients With Urothelial Carcinoma of the Urinary Bladder. American Journal of Clinical Oncology: Cancer Clinical Trials, 2020, 43, 880-888.	1.3	5
89	Progress in prostate cancer prevention. European Journal of Cancer Prevention, 2022, 31, 554-557.	1.3	5
90	ecancermedicalscience. Ecancermedicalscience, 2012, 6, 252.	1.1	4

#	Article	IF	Citations
91	Bladder preservation in non-metastatic muscle-invasive bladder cancer (MIBC): a single-institution experience. Ecancermedicalscience, 2016, 10, 657.	1.1	4
92	Outcomes of robot-assisted simple enucleation of renal masses. Medicine (United States), 2017, 96, e6771.	1.0	4
93	Confirmatory multiparametric magnetic resonance imaging at recruitment confers prolonged stay in active surveillance and decreases the rate of upgrading at follow-up. Prostate Cancer and Prostatic Diseases, 2020, 23, 94-101.	3.9	4
94	Effect of stage and grade migration on cancer specific mortality in renal cell carcinoma patients, according to clear cell vs. non-clear cell histology: A contemporary population-based analysis. Urologic Oncology: Seminars and Original Investigations, 2020, 38, 506-514.	1.6	4
95	Contemporary rates and predictors of open conversion during minimally invasive partial nephrectomy for kidney cancer. Surgical Oncology, 2021, 36, 131-137.	1.6	4
96	Increased Body Mass Index Is a Risk Factor for Poor Clinical Outcomes after Radical Prostatectomy in Men with International Society of Urological Pathology Grade Group 1 Prostate Cancer Diagnosed with Systematic Biopsies. Urologia Internationalis, 2022, 106, 75-82.	1.3	4
97	Robot-Assisted Intracorporeal Orthotopic Ileal Neobladder: Description of the "Shell―Technique. Journal of Clinical Medicine, 2021, 10, 3601.	2.4	4
98	Repeat MRI during active surveillance: natural history of prostatic lesions and upgrading rates. BJU International, 2022, 129, 524-533.	2.5	4
99	Association of statin use and oncological outcomes in patients with first diagnosis of T1 high grade non-muscle invasive urothelial bladder cancer: results from a multicenter study. Minerva Urology and Nephrology, 2022, 73, .	2.5	4
100	The Clinical Role of SRSF1 Expression in Cancer: A Review of the Current Literature. Applied Sciences (Switzerland), 2022, 12, 2268.	2.5	4
101	Finding safe dose-volume constraints for re-irradiation with SBRT of patients with prostate cancer relapse: The IEO experience. Physica Medica, 2021, 92, 62-68.	0.7	4
102	The Effect of Systemic Chemotherapy on Survival in Patients With Localized, Regional, or Metastatic Adenocarcinoma of the Urinary Bladder. American Journal of Clinical Oncology: Cancer Clinical Trials, 2020, 43, 567-574.	1.3	3
103	Robot-assisted inguinal lymphadenectomy: preliminary experience and perioperative outcomes from an Italian referral center. Therapeutic Advances in Urology, 2020, 12, 175628722091338.	2.0	3
104	Adjuvant radiotherapy in node positive prostate cancer patients: a debate still on. when, for whom?. BJU International, 2021, 127, 454-462.	2.5	3
105	A risk-group classification model in patients withÂbladder cancerÂunder neoadjuvant cisplatin-based combination chemotherapy. Future Oncology, 2021, 17, 3987-3994.	2.4	3
106	Active surveillance for prostate cancer: comparison between incidental tumors vs. tumors diagnosed at prostate biopsies. World Journal of Urology, 2021, , 1.	2.2	3
107	Impact of the COVIDâ€19 pandemic on urological cancers: The surgical experience of two cancer hubs in London and Milan. BJUI Compass, 0, , .	1.3	3
108	Clinical evaluation and disease management of PI-RADS 3 lesions. Analysis from a single tertiary high-volume center. Scandinavian Journal of Urology, 2020, 54, 382-386.	1.0	2

#	Article	IF	CITATIONS
109	Minimally invasive versus open radical cystectomy: long term oncologic outcomes compared. Translational Andrology and Urology, 2020, 9, 1006-1008.	1.4	2
110	Metabolic Syndrome Predicts Worse Perioperative Outcomes in Patients Treated With Partial Nephrectomy for Renal Cell Carcinoma. Urology, 2020, 140, 91-97.	1.0	2
111	Insertion of a testicular prosthesis at the time of radical orchiectomy for testicular cancer is safe in patients who will subsequently undergo chemotherapy or radiotherapy. Andrologia, 2020, 52, e13613.	2.1	2
112	Metabolic syndrome predicts worse perioperative outcomes in patients treated with radical prostatectomy for non-metastatic prostate cancer. Surgical Oncology, 2021, 37, 101519.	1.6	2
113	Therapeutic Sequences in the Treatment of High-Risk Prostate Cancer: Paving the Way Towards Multimodal Tailored Approaches. Frontiers in Oncology, 2021, 11, 732766.	2.8	2
114	Penile-sparing surgery for patients with superficial or initially invasive squamous cell carcinoma of the penis: long-term oncological outcomes. Urologic Oncology: Seminars and Original Investigations, 2021, 39, 736.e1-736.e7.	1.6	2
115	Patient Selection for Active Surveillance in the Multi-parametric Magnetic Resonance Imaging Era: A Step Forward in a Rapidly Evolving Field. Annals of Surgical Oncology, 2018, 25, 3423-3424.	1.5	1
116	Adherence to guideline recommendations for multimodality treatment of patients with pT2–3 M0 nonâ€urothelial carcinoma of the urinary bladder: Temporal trends and survival outcomes. International Journal of Urology, 2020, 27, 402-407.	1.0	1
117	Reply by Authors. Journal of Urology, 2020, 203, 503-504.	0.4	1
118	Predictors of Positive Surgical Margins after Robot-Assisted Partial Nephrectomy for Localized Renal Tumors: Insights from a Large Multicenter International Prospective Observational Project (The) Tj ETQq0 0 0 rg81	Γ ‡Ωv erlocl	k 1 0 Tf 50 37
119	Synchronous Robot-Assisted Pulmonary and Urologic Resections for Cancer. Innovations: Technology and Techniques in Cardiothoracic and Vascular Surgery, 2021, 16, 101-103.	0.9	0
120	Splenodiaphragmatic colonic interposition and left hemidiaphragmatic elevation in a patient undergoing robot-assisted radical prostatectomy: a case report. Urology & Nephrology Open Access Journal, 2018, 6, .	0.1	0
121	The role of MRI in the management of a prostate cancer patient with bone and lymph nodes metastases. A case report. Acta Biomedica, 2021, 92, e2021214.	0.3	0
122	Correlation between radiological and biological features and clinical outcomes in early prostate cancer: an exploratory subgroup analysis. Neoplasma, 2022, , .	1.6	0
123	Association between previous negative biopsies and lower rates of progression during active surveillance for prostate cancer. World Journal of Urology, 2022, , 1.	2.2	0